SA
Sarika Anil Kamble
About Sarika Anil Kamble
Data last updated:
Sarika Anil Kamble is a Director at Aboli Hospital Private Limited (since 2018) and Director at Crossandra Pharma Private Limited (since 2016). The companies operate in Healthcare and Chemicals. The 2 current companies with reported revenue have a combined latest revenue of ₹1.28 Cr; the largest is Aboli Hospital Private Limited at ₹97.2 Lakh (FY 2024).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 16 Jan 2018 | 2018 | ₹97.2 Lakh (FY 2024) | Active | |
| Director | 02 Jun 2016 | 2016 | ₹30.8 Lakh (FY 2024) | Active |
Board colleagues of Sarika Anil Kamble
| Name | DIN | Company | Designation |
|---|---|---|---|
| Anil Sadashivrao Kamble | 07528586 | Aboli Hospital Private Limited , Crossandra Pharma Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Sarika Anil Kamble
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sarika Anil Kamble
Sarika Anil Kamble currently holds 2 directorships: Aboli Hospital Private Limited (Director, since 16 Jan 2018, revenue ₹97.2 Lakh (FY 2024)); Crossandra Pharma Private Limited (Director, since 02 Jun 2016, revenue ₹30.8 Lakh (FY 2024)).
Sarika Anil Kamble was first appointed on 02 Jun 2016 as Director at Crossandra Pharma Private Limited. The most recent appointment on record is 16 Jan 2018 at Aboli Hospital Private Limited.
The 2 current companies of Sarika Anil Kamble that report revenue have a combined latest revenue of ₹1.28 Cr: Aboli Hospital Private Limited ₹97.2 Lakh (FY 2024); Crossandra Pharma Private Limited ₹30.8 Lakh (FY 2024).
The current boards of Sarika Anil Kamble's companies include Anil Sadashivrao Kamble (Aboli Hospital Private Limited).